Navigation Links
2 in 1: Multi-tasking protein provides new approaches for anti-tuberculosis drugs
Date:2/15/2011

In a paper published today in PNAS, scientists from the European Molecular Biology Laboratory (EMBL) in Hamburg, Germany, reveal new insights into the workings of enzymes from a group of bacteria including Mycobacterium tuberculosis, the bacterium that causes tuberculosis. The new findings present possible new opportunities for developing organism-specific drugs, which target the pathogen but leave other microorganisms, which are beneficial to us, untouched.

Tuberculosis remains one of the largest threats to human health worldwide, and one of the most frequent causes of death in HIV patients. With the increasing emergence of strains of Mycobacterium tuberculosis that are hyper-resistant to drugs, it becomes ever more urgent that novel treatments be developed, and the search for novel strategies for drug development is an important step in this process.

In the current study, Matthias Wilmanns and his group at EMBL identified a multi-tasking enzyme from Mycobacterium tuberculosis that catalyses reactions on two different molecules, or substrates. In most organisms, cells need two specific enzymes, known as HisA and TrpF, in order to produce two essential amino acids histidine and tryptophan. However, in Mycobacterium tuberculosis, the encoding gene for TrpF is missing, and the two reactions are instead catalysed by a single enzyme, which is able to recognize and bind to two different substrates. This enzyme is known as PriA.

Using the Mycobacterium tuberculosis version of the PriA enzyme as a model, the researchers were able to unravel the hitherto unknown mechanism of bi-substrate specific binding observed in this group of bacteria.

"When we solved the three-dimensional structure of PriA, we found that it has the unique ability to form two different substrate-specific active sites," Wilmanns says: "it can form a reaction-specific active site, or undergo what we call 'substrate-induced metamorphosis' to form a different active site."

To further verify these observations, Wilmanns and colleagues screened 20,000 small molecule compounds, and identified a handful which inhibited both PriA-catalysed reactions but had no effect on TrpF activity.

"We believe that this ability for bi-substrate catalysis in Mycobacterium tuberculosis could be a new opportunity for future drug development," Wilmanns concludes: "This organism-specific reaction process could be exploited, since only the pathogen but none of the other bacteria living in or on humans, many of which are important for our well being, would be targeted."


'/>"/>

Contact: Sonia Furtado
sonia.furtado@embl.de
European Molecular Biology Laboratory
Source:Eurekalert

Related biology news :

1. Blood-clotting protein linked to cancer and septicemia
2. A protein reinforces memory and prevents forgetfulness
3. Pitt team grows arteries with most elastic protein reported, big step for living vascular grafts
4. Scientists link protein to the insulation of the nervous systems wiring
5. New method for rapidly producing protein-polymers
6. New study shows soy protein lowers non-HDL cholesterol significantly more than milk protein
7. New method takes snapshots of proteins as they fold
8. Mayo researchers describe measles viral protein movement
9. Princeton scientists construct synthetic proteins that sustain life
10. Scripps Research chemist devises new method to quantify protein changes
11. Eating low-fat, thanks to lupin proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... FRANCISCO , Feb. 23, 2017   ViaCyte, ... Type 1, a not-for-profit advocacy and education group for ... grant from Beyond Type 1 to support ViaCyte,s efforts ... other insulin-requiring diabetes.  For more than ... cell replacement therapies with a focus on the treatment ...
(Date:2/22/2017)... Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. announced today ... at the Annual Biocom Global Life Science Partnering Conference.  ... 11:15 AM, at the Torrey Pines Lodge, in San ... organizers at Biocom who have chosen our company, amongst ... biotechnology companies, investors, and clinical researchers," said Mr. Chen. ...
(Date:2/22/2017)... ... ... LabRoots , the leading provider of educational and interactive virtual events ... the launch of a new scholarship for young scientists seeking a degree in any ... open to all high school seniors, 17 years or older; as well as those ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and ... Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. ... joins Pennside after more than a decade with leading market research firm, GfK. ...
Breaking Biology Technology: